Back to Stocks

PTGX

Protagonist Therapeutics, Inc
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Protagonist Therapeutics has reached a pivotal financial inflection point, transitioning from a traditional cash-burning biotech into a milestone-driven enterprise.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline swing to profitability, a closer look at the Q1 2026 filing reveals a fragile revenue base heavily dependent on one-off events.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every PTGX filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing depicts a company in the midst of a high-stakes transition. The approval of ICOTYDE and the strategic pivot in the Takeda partnership have provided Protagonist with a massive liquidity cushion and a blueprint for high-margin royalty income. However, the disconnect between reported net income and actual operating cash flow underscores the volatility inherent in the biotech milestone model. Investors are now weighing the company's proven ability to hit clinical milestones against the reality of its ongoing cash burn. The next six months are critical, as the market will look for the rusfertide FDA decision and progress in the obesity pipeline to determine if Protagonist can evolve from a milestone-dependent entity into a diversified commercial-stage biopharmaceutical company.

Selected Quarter

Core Takeaway

The company has transitioned to a net-positive bottom line this quarter, but this is driven by non-recurring milestones rather than sustainable product sales.

Investor Lens

The trade-off between immediate milestone cash and the loss of direct profit-sharing in the U.S. market for rusfertide.

Watch Next

FDA decision on rusfertide for polycythemia vera (PV) expected in Q3 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.48Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 5

Swing to net income of $3.8M from a $11.7M loss YoY.

earnings beat
90%
bullishMay 5

License revenue surged 99% while G&A expenses grew only 13%.

margin expansion
70%
bullishMay 5

Secured $200M immediate payment via Takeda partnership opt-out.

capital raise
80%
bearishMay 5

R&D expenses increased 30% to $46.7M to fund new pipeline trials.

margin compression
50%
bullishMay 5

Swing to net income of $3.8M from a $11.7M loss YoY.

earnings beat
90%
bullishMay 5

License revenue surged 99% while G&A expenses grew only 13%.

margin expansion
70%
bullishMay 5

Secured $200M immediate payment via Takeda partnership opt-out.

capital raise
80%
bearishMay 5

R&D expenses increased 30% to $46.7M to fund new pipeline trials.

margin compression
50%
bullishMay 5

Swing to net income of $3.8M from a $11.7M loss YoY.

earnings beat
90%
bullishMay 5

License revenue surged 99% while G&A expenses grew only 13%.

margin expansion
70%
bullishMay 5

Secured $200M immediate payment via Takeda partnership opt-out.

capital raise
80%
bearishMay 5

R&D expenses increased 30% to $46.7M to fund new pipeline trials.

margin compression
50%
bullishMay 5

Swing to net income of $3.8M from a $11.7M loss YoY.

earnings beat
90%
bullishMay 5

License revenue surged 99% while G&A expenses grew only 13%.

margin expansion
70%
bullishMay 5

Secured $200M immediate payment via Takeda partnership opt-out.

capital raise
80%
bearishMay 5

R&D expenses increased 30% to $46.7M to fund new pipeline trials.

margin compression
50%
bullishMay 5

Swing to net income of $3.8M from a $11.7M loss YoY.

earnings beat
90%
bullishMay 5

License revenue surged 99% while G&A expenses grew only 13%.

margin expansion
70%
bullishMay 5

Secured $200M immediate payment via Takeda partnership opt-out.

capital raise
80%
bearishMay 5

R&D expenses increased 30% to $46.7M to fund new pipeline trials.

margin compression
50%
bullishMay 5

Swing to net income of $3.8M from a $11.7M loss YoY.

earnings beat
90%
bullishMay 5

License revenue surged 99% while G&A expenses grew only 13%.

margin expansion
70%
bullishMay 5

Secured $200M immediate payment via Takeda partnership opt-out.

capital raise
80%
bearishMay 5

R&D expenses increased 30% to $46.7M to fund new pipeline trials.

margin compression
50%
bullishMay 5

Swing to net income of $3.8M from a $11.7M loss YoY.

earnings beat
90%
bullishMay 5

License revenue surged 99% while G&A expenses grew only 13%.

margin expansion
70%
bullishMay 5

Secured $200M immediate payment via Takeda partnership opt-out.

capital raise
80%
bearishMay 5

R&D expenses increased 30% to $46.7M to fund new pipeline trials.

margin compression
50%

Filing History

10-QMay 5, 2026
Expand Sequence

The Q1 2026 filing depicts a company in the midst of a high-stakes transition. The approval of ICOTYDE and the strategic pivot in the Takeda partnership have provided Protagonist with a massive liquidity cushion and a blueprint for high-margin royalty income. However, the disconnect between reported net income and actual operating cash flow underscores the volatility inherent in the biotech milestone model. Investors are now weighing the company's proven ability to hit clinical milestones against the reality of its ongoing cash burn. The next six months are critical, as the market will look for the rusfertide FDA decision and progress in the obesity pipeline to determine if Protagonist can evolve from a milestone-dependent entity into a diversified commercial-stage biopharmaceutical company.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.